Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Doc83 & Joey, I agree, we can't get rid of RM in favour of Polygon. RM has far more concern for PI's than a ruthless hedge fund.
As an aside, I believe that even if SNG is taken off AIM the 30% rule still applies.
Aether, I think the deep dive results may well encourage a bigger, government backed trail. But even without them the drug warrants one. With the benefit of hindsight, they should've gone that route to begin with.
They are a research company, they will be fascinated by the results of the deep dive. That is different to the SP, that requires it to be in another Phase 3 to lift it, and if the results are better, or even just the numbers achieved with the same results... happy days for us all.
I believe SNG were a little unlucky in their Phase 3.... but they were unlucky with the AZN trial too... you can either believe that they will keep being unlucky, or that perseverance wins. I'm in the latter camp.
Aether... baby steps first.... I think the question should be... What value does a research company have with a life saving (wholly owned) drug in a Phase 3 trial, that is being supported by a government? A big Pharma will be far more interested in SNG if it is on a paid for trial... it, obviously, means they don't have to pay for it.
I don't know the answer, but I believe it is well north of £50m. Someone on here I am sure will have some examples.
I personally think the % chance of EUA is less than 10%. I'd be delighted amazed if we did, of course. This board often gets a bit too over excited, a possible EUA is a good example, and then disappointed with RM, when in fact, he has always been quite conservative and understated.
RM has stated that he is in talks with governments about bigger platform trials, this has been reinforced by other posters and boards, some of whom have been more recently in touch with RM. I would love to see us on Active 3 P3, as I think that 36% above SOC is still pretty exciting in the hospital setting.
When we do get on a platform trial, I think we will (which is at no cost to SNG, except for the product) then I believe that RNS will bring us back to well above 35p. It is for that reason that I remain invested.
Not sure why there is constant concern over whether its a buy or a sell.
For every seller there is a willing buyer and vice versa.
The price goes down if no-one wants to buy, and up if no-one wants to sell.... it's the simple law of supply and demand.
Hi Sid
I've only had a quick glance at the Eiger outpatient Phase 3... so I may be wrong in my assumptions... but I find it interesting that in order to get to 60% it had to be administered within 3 days of symptoms, at 7 days it drops to 40%. And that, even in this huge trial, only 4 died on the placebo, and 1 on the drug. So they had to inject 2000 vulnerable people to save 3 lives. What is the cost of those lives? Of course every life is invaluable in my mind, but that's not how it works. Perhaps SNG outpatient in Active 2 will be similar.... we don't know yet.
If it is, it makes me think that Sprinter/hospitalised, if we can get good data on the deep dive, is the route forward. 36% on top of SOC is not a small figure.
But the case that Interferons work is further proved in the case of Eiger.
New York Times 24th March:
Bracing for the BA.2 wave
Barely two months after the Omicron wave, U.S. epidemiologists are already warning of another swell in the pandemic.
Though Covid case numbers are falling in most of the country, scientists warn that the quiet may soon give way to another surge, driven by an Omicron subvariant, BA.2. It is already fueling an increase in cases in 18 countries, including Britain, France, Germany and Italy.
There are still many question marks about a potential BA.2 wave. To understand what might lie ahead, I spoke with my colleague Benjamin Mueller, a health and science reporter.
What do we know about BA.2?
We know that BA.2 is more contagious than the version of Omicron that spread through the U.S. this winter. We know that some places like New York City are seeing early signs of cases ticking up, though at very low levels overall. And BA.2 is quickly becoming more prevalent in some places. But whether that turns into a wave — as some countries in Europe are seeing — is hard to know for sure.
What’s the worst case scenario?
A worse-case scenario is that the U.S. follows the path of the U.K., where not only have cases surged, but so have hospitalizations.
The U.S. has vaccinated and boosted people at lower rates than Western Europe. Even now, Americans are dying from Covid at far higher rates than people in Western Europe. And experts worry that those low booster and vaccination rates, especially in older people, could put the U.S. in a vulnerable position once BA.2 takes hold.
Plus, there’s the fear that even though some parts of the U.S. have effectively been without restrictions for months, reduced masking in other places could help speed a rise in cases.
* Just a couple of paragraphs from a longer article.
Apologies if posted before.... from The Lancet 10th March. Total reported Covid deaths for 2020 were 5.94m, though excess deaths, people dying because of the pandemic, was closer to 18.2m.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02796-3/fulltext?dgcid=raven_jbs_aip_email
Surely finding and stockpiling a suitable drug for future pandemics must still be front of mind for all governments.
There is indeed, aunt and uncle have both just caught it, late 70's, and also lots of their friends, all had boosters in September. One who had it before (prob delta) has it much worse this time. A few of my friends with it too, there suddenly seems to be a lot of it around.
Great to see some positivity returning, after such disappointing news for all LTH's.
I believe in the drug, it clearly works. My only concern is the declining numbers of patients for future trials, for any new drug to treat Covid. Do we know how many patients are needed to complete the SNG Active 2 Phase 3... or is this now an unknown?
TLWilliams.... couldn't agree more. I also found Brooke's email far more reassuring and less confusing that the RNS... especially with regards the confusion on this board over use of Steroids
We now have a media specialist and Brooke.... apart from the fact that there is no point having a dog and barking yourself..... RM has lost more money 'on paper' than anyone on this board.... I doubt he is feeling 'buoyant' about it.... best to keep him away from the mic.... at least until we have good news re updates on Active 2.
Thanks Veteran10....
This makes it clearer that they believe it is the improved SOC (steroids and Remdesivir) they think contributed to the reduction from 87% to 36.3%, in Phase 2 compared to Phase 3.... and not the fact that SNG does not work with steroids.
If so, this means COPD/Asthma (where steroids are also SOC) are still in play and of huge value to a big Pharma to pick up and develop in the years to come. Makes sense to me why Polygon continue to buy.
Axe... I understand how you feel. Grief to anger. It is also good to explore all possibilities in your mind, negative and positive... not just irrational hope..
For what's it's worth, I know a friend of RM's. He's honest to the core. Perhaps inexperienced, maybe out of his depth... but not dishonest.
Polygon are not buying to create some kind of smoke screen, they're a ruthless hedge fund, they see buying now as an opportunity to make money. SNG Mcap is ridiculously low for a company currently in a paid for Phase 3 USA trial. At the same time I don't see Polygon as 'lowering their average'.... they don't think that way, only we do. They've wiped the slate clean and see this as a new 'project'. If they didn't see an upside they'd have dumped and moved on to one of their many other 'projects'... time is money. If I was braver, and had limitless funds, I'd be buying up too.
I personally don't want to hear from RM until he has good news... anything else will do more harm than good.
I don't see the share price improving in the short term, and I am looking at this as a longer term investment now. The clever people will be dusting themselves off and doing the same as Polygon... within their own budgets.
"Buy when there's blood on the streets" ... never truer than in this share today.
Pull yourself together guys, we've all been through difficult challenges... what's done is done.. life's not about how far we fall, but how well we bounce.